Jump to Content Jump to Main Navigation
HOME BROWSE
CLINICAL RESOURCES DRUG INFORMATION EDUCATION AND TRAINING PHARMACY PRACTICE CAREER DEVELOPMENT
AJHP DRUG INFORMATION PROFESSIONAL DEVELOPMENT
Sign in Sign up
Advanced Search Help
Sign in Sign up
HOME BROWSE
CLINICAL RESOURCES DRUG INFORMATION EDUCATION AND TRAINING PHARMACY PRACTICE CAREER DEVELOPMENT
AJHP DRUG INFORMATION PROFESSIONAL DEVELOPMENT
Advanced Search Help

Cover Dyslipidemia: Contemporary Evaluation and Management eReport
 

 

  • Front Matter
    • Preliminary Material
  • Introduction
    • Table 1-1: Cholesterol Concentrations
    • Table 1-2: Epidemiologic Data for Dyslipidemia
    • Figure 1-1: Approach to Management of Dyslipidemia
    • Table 1-3: Comparison of ATP-III Guidelines, ACC/AHA 2013 Guidelines, and NLA Recommendations
  • Pathophysiology
    • Clinical Presentation, Diagnosis, and Disease Classification
    • Table 1-4: Major Risk Factors for ASCVD
    • Table 1-5: Criteria for Classification of ASCVD
    • Table 1-6: National Lipid Association Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels to Consider Drug Therapy
  • General Treatment Principles
    • Table 1-7: Components of Dietary Recommendations
    • American College of Cardiology/American Heart Association Guidelines
    • Table 1-8. Statin intensity
    • National Lipid Association Recommendations
    • Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement
    • Table 1-10. Drugs that Can Lead to or Worsen Dyslipidemias
  • Pharmacotherapy
    • Statins
    • Cholesterol Absorption Inhibitors
    • Bile Acid Sequestrants
    • Fibric Acid Derivatives
    • Nicotinic Acid
    • Omega-3 Fatty Acids
    • Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies
  • Monitoring
    • Table 1-12: Lipid Effects of Nonstatin Agents
    • Table 1-13: Clinical Conditions that Can Worsen Lipid Profiles
  • Clinical Questions and Controversies
    • What Impact Do Statins Have on Cognitive Function?
    • Do Statins Cause or Worsen Type 2 Diabetes?
    • Are Statins Safe to Use in Patients with Chronic Liver Disease?
    • What Drug-Drug Interactions Impact Statin Therapy?
    • Can Fibrates Be Safely Added to a Statin for the Management of Hypertriglyceridemia?
    • What Is the Best Way to Manage Suspected Statin-Induced Myalgia?
    • Should Co-enzyme Q10 Be Recommended for the Treatment and/or Prevention of Statin-Associated Muscle Aches?
    • Which Risk Calculator Is Best?
    • What Is the Best Strategy to Manage Residual Cardiovascular Risk?
    • What LDL-C Level Is Too Low?
    • Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?
    • What Is the Role of CRP in Determining CHD Risk and LDL-C Goals?
  • Back Matter
    • Future Treatments
    • References

Table 1-12: Lipid Effects of Nonstatin Agents

in Dyslipidemia: Contemporary Evaluation and Management eReport
Editors:
Evan M. Sisson
,
McKenzie Calhoun
, and
Michael A. Crouch
DOI:
https://doi.org/10.37573/9781585284719.022
Restricted access
Email this content

Share Link


Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully

About ASHP Contact Us Correction Notices Customer Relations
FAQs Information for Authors Libraries and Institutions Rights and Permissions

© 2023 American Society of Health-System Pharmacists. All Rights Reserved.

Powered by: PubFactory

Powered by PubFactory
  • [34.232.62.64]
  • 34.232.62.64
Close
Edit

Character limit 500/500

@!

Character limit 500/500